ATE514718T1 - Peptabody für krebsbehandlung - Google Patents

Peptabody für krebsbehandlung

Info

Publication number
ATE514718T1
ATE514718T1 AT04725746T AT04725746T ATE514718T1 AT E514718 T1 ATE514718 T1 AT E514718T1 AT 04725746 T AT04725746 T AT 04725746T AT 04725746 T AT04725746 T AT 04725746T AT E514718 T1 ATE514718 T1 AT E514718T1
Authority
AT
Austria
Prior art keywords
isolated
recombinant fusion
peptabody
fusion peptabody
cancer treatment
Prior art date
Application number
AT04725746T
Other languages
English (en)
Inventor
David Deperthes
Sylvain Cloutier
Jean-Pierre Mach
Nils Holler
Omar Fattah
Original Assignee
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne filed Critical Univ Lausanne
Application granted granted Critical
Publication of ATE514718T1 publication Critical patent/ATE514718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
AT04725746T 2003-04-04 2004-04-05 Peptabody für krebsbehandlung ATE514718T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46049003P 2003-04-04 2003-04-04
PCT/IB2004/001049 WO2004087766A2 (en) 2003-04-04 2004-04-05 Peptabody for cancer treatment

Publications (1)

Publication Number Publication Date
ATE514718T1 true ATE514718T1 (de) 2011-07-15

Family

ID=33131924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04725746T ATE514718T1 (de) 2003-04-04 2004-04-05 Peptabody für krebsbehandlung

Country Status (12)

Country Link
US (1) US20060233808A1 (de)
EP (1) EP1613661B1 (de)
JP (1) JP2007527206A (de)
KR (1) KR20060017585A (de)
CN (1) CN1798770B (de)
AT (1) ATE514718T1 (de)
AU (1) AU2004226162A1 (de)
BR (1) BRPI0409554A (de)
CA (1) CA2521393A1 (de)
MX (1) MXPA05010575A (de)
NO (1) NO20055209L (de)
WO (1) WO2004087766A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5830217B2 (ja) * 2006-02-23 2015-12-09 ヴィアサイト インコーポレイテッド 分化可能細胞の培養に有用な組成物及び方法
WO2009103072A2 (en) * 2008-02-14 2009-08-20 The Trustees Of The University Of Pennsylvania Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
AU2009314534B2 (en) 2008-11-12 2014-06-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma
WO2010103475A2 (en) 2009-03-10 2010-09-16 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP2013540125A (ja) * 2010-09-30 2013-10-31 ゴラブ，エミール 水中細菌抽出物−濃縮物からの乾燥粉末の調製方法
KR101633159B1 (ko) * 2013-11-28 2016-06-23 부경대학교 산학협력단 클라미도모나스 유래 활성 펩타이드를 유효성분으로 포함하는 위장 질환 치료 및 예방용 조성물
KR101587622B1 (ko) * 2014-05-23 2016-01-22 한국과학기술원 상피세포 성장인자 수용체의 세포외 도메인과 결합하는 신규 폴리펩타이드
WO2019086394A1 (en) * 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
EP3752486A4 (de) * 2018-02-15 2022-07-06 Children's National Medical Center Heptamethincyanine zur verwendung als fluoreszenzmarker der gallen- und nierensysteme
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CN116370399A (zh) * 2021-12-31 2023-07-04 康码（上海）生物科技有限公司 用于病毒的防护和/或治疗的膜剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
AU6171194A (en) * 1993-02-05 1994-08-29 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
EP0938571B8 (de) * 1996-10-28 2008-07-02 University of Lausanne Verfahren zur oligomerisation von peptiden
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2001005433A2 (en) * 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
EP2275557A1 (de) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
AU2001273559A1 (en) * 2000-07-18 2002-01-30 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
RU2003134180A (ru) * 2001-05-08 2005-02-10 Мерк Патент ГмбХ (DE) Комбинированная терапия, использующая антитела к egfr и антигормональные средства
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule

Also Published As

Publication number Publication date
NO20055209L (no) 2006-01-02
WO2004087766A3 (en) 2004-12-16
CN1798770A (zh) 2006-07-05
EP1613661A2 (de) 2006-01-11
CN1798770B (zh) 2010-06-09
BRPI0409554A (pt) 2006-04-25
CA2521393A1 (en) 2004-10-14
KR20060017585A (ko) 2006-02-24
WO2004087766A2 (en) 2004-10-14
NO20055209D0 (no) 2005-11-04
MXPA05010575A (es) 2006-03-09
US20060233808A1 (en) 2006-10-19
JP2007527206A (ja) 2007-09-27
AU2004226162A1 (en) 2004-10-14
EP1613661B1 (de) 2011-06-29

Similar Documents

Publication Publication Date Title
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE514718T1 (de) Peptabody für krebsbehandlung
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
MX2009002816A (es) Proteinas de fusion de albumina.
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
AU2002305450A1 (en) Proteomimetic compounds and methods
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
PH12012502272A1 (en) Biological materials related to her3
WO2008153933A3 (en) Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MX341317B (es) Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
PL2089433T3 (pl) Terapia ukierunkowana na katepsynę S
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2006047728A3 (en) Bmp gene and fusion protein
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2009093246A3 (en) Clusterin derived peptide
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
DK1602669T3 (da) Antistof mod et tumor-specifikt antigen som target

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties